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Vitronectin and plasminogen activator inhibitor-1 (PAI-1)
are proteins that interact in the circulatory system and pericellular region to regulate fibrinolysis, cell adhesion, and migration. The interactions between the two proteins have been
attributed primarily to binding of the somatomedin B (SMB)
domain, which comprises the N-terminal 44 residues of
vitronectin, to the flexible joint region of PAI-1, including residues Arg-103, Met-112, and Gln-125 of PAI-1. A strategy for
deletion mutagenesis that removes the SMB domain demonstrates that this mutant form of vitronectin retains PAI-1 binding (Schar, C. R., Blouse, G. E., Minor, K. M., and Peterson, C. B.
(2008) J. Biol. Chem. 283, 10297–10309). In the current study,
the complementary binding site on PAI-1 was mapped by testing for the ability of a battery of PAI-1 mutants to bind to the
engineered vitronectin lacking the SMB domain. This approach
identified a second, separate site for interaction between
vitronectin and PAI-1. The binding of PAI-1 to this site was
defined by a set of mutations in PAI-1 distinct from the mutations that disrupt binding to the SMB domain. Using the
mutations in PAI-1 to map the second site suggested interactions between ␣-helices D and E in PAI-1 and a site in
vitronectin outside of the SMB domain. The affinity of this
second interaction exhibited a KD value ⬃100-fold higher
than that of the PAI-1-somatomedin B interaction. In contrast to the PAI-1-somatomedin B binding, the second interaction had almost the same affinity for active and latent
PAI-1. We hypothesize that, together, the two sites form an
extended binding area that may promote assembly of higher
order vitronectin-PAI-1 complexes.

Vitronectin is a circulatory protein that interacts with several
other plasma components that regulate coagulation and fibrinolysis, cell lysis via the complement cascade, and cell binding
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and migration in an integrin-dependent and urokinase-type
plasminogen activator receptor-dependent fashion (1, 2). An
interaction with vitronectin that has been widely studied occurs
with the serine protease inhibitor (or serpin), PAI-1,2 the primary inhibitor of urokinase-type plasminogen activator (uPA)
and tissue-type plasminogen activator (tPA). Most circulating
PAI-1 is found in a complex with vitronectin (3). The formation
of the complex between vitronectin and PAI-1 is presumed to
be physiologically significant in several respects. Binding of
vitronectin to PAI-1 stabilizes the active conformation of the
serpin, increasing the half-life for its conversion to the inactive,
so-called latent state, and maintains its protease inhibitory
properties for a prolonged period (4, 5). PAI-1 binds to the
N-terminal ⬃50-amino acid somatomedin B (SMB) domain of
vitronectin. The binding of PAI-1 competes with the binding of
the urokinase-type plasminogen activator receptor to this
domain and with the binding of integrins to the adjacent RGD
sequence (for a review, see Ref. 6). Moreover, PAI-1 has been
reported to induce oligomerization of vitronectin (7–10).
The structural basis for the transition of PAI-1 from an active
to inactive or latent serpin is understood in exquisite detail
thanks to several x-ray crystallographic studies on the two
forms of the inhibitor (11–15). PAI-1 exhibits the canonical
serpin fold (reviewed in Ref. 16), with a central five-strand
␤-sheet from which protrudes the reactive center loop (RCL),
the peptide sequence that houses the specific target sequence
recognized by proteases, tPA and uPA. The conversion of PAI-1
to its inactive, latent form results from repositioning of the
RCL, whereby it becomes incorporated as a sixth strand in the
central ␤-sheet, and the overall fold of the protein adopts a
structure that is more thermodynamically favored (17). The
identification of the primary binding site for vitronectin on
PAI-1 as the flexible joint region, localized in an area defined by
s2A, hE, and hF and comprising, among others, residues Arg103, Met-112, and Gln-125 (18), was instructive for understanding the mechanism by which vitronectin stabilizes PAI-1
(16, 18 –23). By binding to this flexible joint region at the “base”
of central ␤-sheet A, vitronectin opposes expansion of the
␤-sheet, which is required to accommodate the RCL as a sixth
2

The abbreviations used are: PAI-1, plasminogen activator inhibitor type 1;
RCL, reactive center loop; r⌬sBVN, recombinant vitronectin lacking the
SMB domain due to a deletion of residues 1– 40; SMB, somatomedin B; SPR,
surface plasmon resonance; uPA, urokinase-type plasminogen activator;
tPA, tissue-type plasminogen activator; mAb, monoclonal antibody; RU,
response unit(s).
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strand. In this way, the active conformation of PAI-1 is stabilized by vitronectin. Besides this purely steric effect, other evidence suggests that the SMB domain induces extensive conformational changes in PAI-1 (24, 25).
Although there is ample information on the three-dimensional structure of PAI-1, much less is known about vitronectin.
The only domain for which there is high-resolution information is the SMB domain (15, 26 –31), which is the region of
vitronectin that binds to the flexible joint region in PAI-1 and
stabilizes the serpin. A co-crystal of a recombinant SMB
domain and PAI-1 has provided useful information about the
intermolecular contacts made in this complex (15). The PAI-1binding site within the SMB domain is mostly limited to a single-turn ␣-helix, the only recognizable secondary structural
element in this small disulfide-rich domain (15, 26 –28).
In a recent study (32), we demonstrated that a deletion
mutant of vitronectin lacking the SMB domain retains PAI-1
binding activity, although with a reduced affinity. These data
suggest that PAI-1 should contain a second vitronectin-binding
site to provide the needed complementary interactions
required for binding to vitronectin outside of the SMB domain.
To test this idea, the deletion mutant of vitronectin lacking the
SMB domain (r⌬sBVN (32)) was used to screen for binding to a
battery of PAI-1 mutants. The results define a second vitronectin-binding site on PAI-1 that is distinct from the SMB-binding
site, both in location and binding properties, although it is
localized close to the SMB-binding site. Key questions to be
addressed regarding the significance of this other binding site
include the following. Where is the second site located relative
to the flexible joint region of PAI-1? Does binding of vitronectin
to this site stabilize the active conformation of PAI-1? How do
the kinetics of binding to the second site compare with the
binding to the SMB domain?

EXPERIMENTAL PROCEDURES
Materials—Native vitronectin was purified from human
plasma using a modified protocol of the method developed by
Dahlbäck and Podack (33, 34). A recombinant form of vitronectin
lacking the somatomedin B domain (r⌬sBVN) was expressed in
the baculovirus FastBac system and purified as described (32).
PAI-1 was produced according to the method outlined by Jensen
et al. (21). The numbering used to denote the amino acid positions
in PAI-1 throughout the present work is Ser-1—Ala-2—Val-3—
His-4 —His-5, according to Andreasen et al. (35). Latent PAI-1
was generated by incubating PAI-1 in running buffer for 7 days at
25 °C at a concentration of 5 M. Incubation with uPA followed by
SDS-PAGE to test for covalent, inactive serpin-uPA complexes
was used to assay for PAI-1 activity and conversion to the latent
form over time. Two versions of the SMB domain were used. One
form (residues 1–51) was purified from a cyanogen bromide digest
of human vitronectin as described (26). Another form (residues
1– 47) was produced as a recombinant protein in Pichia pastoris
and was a kind gift from Michael Ploug (Finsen Laboratory,
Copenhagen, Denmark). The two forms are functionally and
structurally indistinguishable (29). All other reagents were of analytical reagent grade or better.
Assay for Rate of Conversion of PAI-1 to a Latent Form—The
assay for measuring the rate at which PAI-1 converts to the
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latent form was performed as described (18). PAI-1 (10 g/ml
final concentration) and vitronectin (2-fold molar excess over
PAI-1) were incubated at 37 °C in HEPES-buffered saline with
0.25% gelatin. At various time points over a period of 2.5 h,
samples were withdrawn for determination of the specific
inhibitory activity of PAI-1 by titration against a fixed concentration of uPA. The PAI-1 activity was plotted as a function of
incubation time, and the functional half-life of PAI-1 was calculated by fitting the data to a simple exponential decay.
Analysis of PAI-1 Binding to r⌬sBVN and Full-length
Vitronectin by Surface Plasmon Resonance (SPR)—For matters
of convenience with multiple instruments in the various laboratories, SPR experiments for analysis of binding of PAI-1 variants to r⌬sBVN or full-length vitronectin were performed on a
Biacore XTM, Biacore 3000TM, or Biacore T100TM instrument
equipped with CM5TM chips. There were no discernable differences between the results obtained by the three instruments.
The running buffer used contained 10 mM HEPES, pH 7.4, 140
mM NaCl, 3 mM EDTA, 0.005% Tween-20, and 0.1% polyethylene glycol 8000. All solutions were filtered and degassed prior
to use in the SPR experiments. Full-length vitronectin or
r⌬sBVN was coupled directly to the surface of a CM5TM chip
with the standard amine coupling protocol. A solution of 30
g/ml r⌬sBVN or vitronectin in 10 mM sodium acetate, pH 4.5,
was injected for coupling until the desired density was achieved.
(Note that higher or lower densities of protein were coupled
strategically to measure equilibrium saturation binding or
determine kinetics for on- and off-rates.) Ethanolamineblocked empty flow cells were used as reference. When necessary, regeneration of the flow cells between runs was achieved
by injecting pulses of 10 mM glycine/HCl, pH 2.0, and/or 0.05%
SDS in running buffer until base-line levels were acquired.
To determine the affinity of PAI-1 binding to full-length
vitronectin or r⌬sBVN, samples of PAI-1 diluted in running
buffer were injected into an array of concentrations ranging
from 0.25 to 1500 nM at a flow rate of 30 l/min. After discontinuation of injection, the dissociation reaction was followed
for a period of time. Rate constants for association (kon) and
dissociation (koff) and equilibrium dissociation constants (KD)
were determined in one of three ways. In most cases, the constants were determined by fitting the data to a 1:1 binding
model using of the Biacore software. In other cases, koff values
were first determined manually from the time courses of dissociation using the Biacore software. The calculated koff values,
evaluated over a concentration range of 10 to 250 nM PAI-1,
were shown to be concentration-independent, as expected for
dissociation of the complex. The kon values were determined by
following the association phase at different PAI-1 concentrations. In either case, the apparent association rate constants
(kon,app) were determined by a fit (global with the Biacore software package or individual curve first for the manual data treatment) to Equation 1,

关 bound PAI-1兴 ⫽ A ⫻ 共1 ⫺ exp共共⫺kon,app兲 ⫻ t兲兲

(Eq. 1)

where A is the steady state level.
The true kon values were then determined from Equation 2.
k on ⫽ 共kon,app ⫺ koff兲/关PAI-1兴

(Eq. 2)
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The equilibrium dissociation constant, KD, was then calculated
as koff/kon.
Finally, in some cases the association and dissociation rates
were too fast to be determined. In these cases, the KD values
were calculated according to the method outlined by Rich and
Myszka (36) for use of SPR in an equilibrium binding approach.
The steady state binding values were plotted against the PAI-1
concentration and fit by nonlinear least squares to the equation,

冉冊

C
KD
R⫽
C
1⫹
KD
R max

(Eq. 3)

where R is the observed response, Rmax is the maximal response,
C is the analyte concentration, and KD is the equilibrium dissociation constant.
To form the SMB domain-PAI-1 complexes, varying molar
ratios of native SMB to a fixed concentration of active or latent
PAI-1 (0.7 M) were incubated for 30 min at room temperature
before injection at a flow rate of 20 l/min over either monomeric vitronectin or r⌬sBVN.
For the monoclonal antibody blocking experiments, the antibodies were incubated with PAI-1 at 1:1 and 1:3 (PAI-1:antibody) molar ratios for 10 min at room temperature in running
buffer. After this incubation period, the sample was injected at
a flow rate of 20 l/min over immobilized r⌬sBVN.

RESULTS
The Deletion Mutant of Vitronectin Lacking the SMB Domain
Does Not Stabilize the Active Conformation of PAI-1—One of
the key consequences of vitronectin binding to PAI-1 is stabilization of the active serpin, with its RCL exposed and poised to
act as bait for target proteases. The structural details of this
stabilizing interaction have been attributed to binding of PAI-1
to the SMB domain of vitronectin (15, 37, 38). The intrinsic rate
of conversion of wild-type PAI-1 in the absence and presence of
added full-length vitronectin or r⌬sBVN was measured by
monitoring inhibition of uPA over time. In isolation, PAI-1
exhibits a half-life of 67 ⫾ 3 min (n ⫽ 15) for conversion to the
latent, inactive form. Full-length vitronectin stabilizes the serpin, increasing the half-life of the active form to 121 ⫾ 17 min
(n ⫽ 12, p ⫽ 0.0001), whereas the deletion mutant appears to
have no effect on PAI-1, which exhibits a half-life of 75 ⫾ 30
min (n ⫽ 8) in the presence of added r⌬sBVN (p ⫽ 0.013).
Comparison of Binding of PAI-1 to r⌬sBVN and Full-length
Vitronectin—The binding of PAI-1 to either full-length
vitronectin or r⌬sBVN was followed using SPR. Initial experiments designed to detect weaker PAI-1-vitronectin interactions were performed with high PAI-1 concentrations (400 nM)
and a high density of vitronectin or the r⌬sBVN variant on the
chip. The sensorgrams of active and latent PAI-1 binding to
either vitronectin or r⌬sBVN are shown in Fig. 1. The data in
Fig. 1, top panel, with immobilized full-length vitronectin confirm the substantially weaker binding that latent PAI-1 exhibits
for full-length vitronectin and clarify kinetic contributions to
the overall low affinity of the interaction. Although the association phase with latent PAI-1 shows interaction with vitronecOCTOBER 17, 2008 • VOLUME 283 • NUMBER 42

FIGURE 1. Characterization of the binding of active and latent PAI-1 to
full-length vitronectin and r⌬sBVN by SPR. Active (solid lines) or latent (dotted lines) wild-type PAI-1 at a concentration of 400 nM was injected at a flow
rate of 20 l/min over a chip with 8000 RU of full-length vitronectin (top panel)
or a chip with 6000 RU of r⌬sBVN (bottom panel).

tin, dissociation occurs at a high rate (t1⁄2 ⬃ 10 s), yielding an
overall weak affinity (Fig. 1, top panel, dashed line). The binding
behavior is clearly different with active PAI-1, which exhibits a
slow off-rate in the dissociation phase of the sensorgram (Fig. 1,
top panel, solid line).
SPR experiments with active and latent PAI-1 confirmed that
both forms of PAI-1 bind to r⌬sBVN (Fig. 1, bottom panel);
latent wild-type PAI-1 binds r⌬sBVN slightly more weakly,
with an approximate 20% reduction in the steady state level
compared with active PAI-1. Nevertheless, the differences
between association and dissociation kinetics with r⌬sBVN
immobilized on the chip are not nearly as marked as those
observed in the case of full-length vitronectin. Notably, the dissociation phases are quite rapid for both active and latent forms
of PAI-1, with half-lives around 5 s, akin to the dissociation
kinetics observed with latent PAI-1 binding to full-length
vitronectin and clearly different from the very slow dissociation
of active PAI-1 from full-length vitronectin.
Analysis of the Binding of Active and Latent PAI-1 to
r⌬sBVN—To compare the binding of active and latent PAI-1 to
the two different forms of vitronectin in detail, we performed a
series of experiments that would accomplish a more quantitative characterization of binding by SPR. The association and
dissociation time courses and steady state binding were followed at different PAI-1 concentrations ranging from 0.4 to
1000 nM, using a chip with ⬃600 RU of r⌬sBVN. Binding isotherms were generated by measuring the level of steady state
binding at varying concentrations of active and latent PAI-1 to
r⌬sBVN on the chip, as described previously (32). Consistent
with our previous report, the equilibrium binding experiments
JOURNAL OF BIOLOGICAL CHEMISTRY
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TABLE 1
Effect of mutations on PAI-1 binding to r⌬sBVN as analyzed by SPR
PAI-1 (400 nM) was injected at a flow rate of 20 l/min over a chip coated with 8000
RU of r⌬sBVN. The steady state binding levels were normalized to the average
active wild-type PAI-1 steady state binding level in the same experiment. Average
values are given ⫾ S.D. with the number of replicates in parentheses. Additional
PAI-1 mutants with single-point mutations that were tested but for which binding
was not significantly different (reduced by more than 50%) compared with the wild
type were E55A, Q57A, Q58A, Q59A, Q61A, K71A, K71A/Y81A, R78A, K82A,
M85A, P87A, W88A, K90A, D91A, E92A, S94A, T96A, F116A, S121A, T122A,
K178A, K231A, and D233A. All of the mutants shown in this table had a significantly
reduced binding as compared with wild-type PAI-1 (p ⬍ 0.01).

FIGURE 2. Determination of the KD value for binding of PAI-1 to r⌬sBVN.
SPR was used as a steady state method for determining the KD value for binding of PAI-1 forms to the mutant vitronectin lacking the SMB domain, as
described under “Experimental Procedures.” Varying concentrations of active
wild-type PAI-1 (F), latent PAI-1 (f), or active PAI-1 R117E/R120E () were
injected across a chip with 600 RU of immobilized r⌬sBVN. The steady state
binding levels obtained from this concentration series were normalized and
plotted versus the concentration of PAI-1. The points were fit to the 1:1 interaction model (Equation 3) to yield a KD of 29 ⫾ 3 nM for the binding of active
wild-type PAI-1, a KD of 120 nM for the binding of latent PAI-1, and a KD of
480 ⫾ 70 nM for the binding of the active form of R117E/R120E to r⌬sBVN.

with active PAI-1 gave a KD value of 29 ⫾ 3 nM. Evaluation of the
rates of association and dissociation under these conditions
gave koff ⫽ 0.049 ⫾ 0.010 s⫺1 and kon ⫽ 1.17 ⫾ 0.17 ⫻ 106
⫺1 ⫺1
M s
(n ⫽ 7). KD calculated from the kinetics in SPR is 42 nM.
Latent PAI-1 binds to r⌬sBVN with a KD value of ⬃120 nM (Fig.
2). Thus, latent PAI-1 binds only somewhat more weakly to the
second site on vitronectin, which lies external to the SMB
domain.
Mapping the Binding Site in PAI-1 That Recognizes Residues
Outside of the SMB Domain in r⌬sBVN—To probe for an additional vitronectin-binding site within PAI-1 that is complementary to the site on vitronectin that lies external to the SMB
domain (32), monoclonal antibodies specific for regions of
PAI-1 were tested for their ability to block binding to r⌬sBVN.
The monoclonal antibodies were preincubated with both active
and latent PAI-1 before being injected over an r⌬sBVN chip.
The monoclonal antibodies mAb-1 (39) and mAb-6 (40), with
respective binding epitopes localized to ␣-helix C and ␣-helix F,
did not inhibit the binding of PAI-1 to r⌬sBVN. However, two
monoclonal antibodies, 33B8 (41) and mAb-7 (42), blocked
binding of PAI-1 to r⌬sBVN, with 33B8 and mAb-7 reducing
the binding of latent PAI-1 to 37 or 22% of its original value,
respectively, and reducing the binding of active PAI-1 to less
than 50% of its original value. The epitopes for these antibodies
are composed of residues from the loop connecting ␣-helix D
and ␤-strand 2A, from ␤-strand 3A, and from ␤-strand 2B; the
epitope for mAb-7 was mapped to Trp-88, Lys-90, Asp-91, Lys178, and His-231 (42, 43).
The general localization of the binding site, apparent from
the experiments using monoclonal antibodies, was refined by
testing a battery of PAI-1 mutants for binding to r⌬sBVN. To
screen a larger number of mutants, we measured the steady
state level of their binding to r⌬sBVN immobilized on a Biacore
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PAI-1 variant

Latent

Active

Wild type
K82E
R117E/R120E
R103A/M112A/Q125A
K71A/R78A/Y81A/K82A
W177F

79 ⫾ 3 (6)
48 ⫾ 8 (2)
8 ⫾ 1 (6)
32 ⫾ 10 (5)
12 ⫾ 1 (2)
8 ⫾ 6 (2)

100
28 ⫾ 1 (2)
11 ⫾ 1 (6)
60 ⫾ 21 (6)
27 ⫾ 1 (4)
37 ⫾ 18 (5)

chip, passing latent PAI-1 over the chip in concentrations ranging from 1 to 2000 nM. The data are summarized in Table 1,
reporting the steady state binding of the mutants relative to that
of wild-type PAI-1 at a concentration of 400 nM, a value slightly
above the KD value described above for binding of latent PAI-1
to r⌬sBVN. Under these conditions, binding is subsaturating,
and the KD is a major determinant of the total binding. We
found that mutant forms of PAI-1 with a number of charge
reversal mutations or multiple alanine substitutions reduced
the binding substantially. The implicated residues are localized
in ␣-helix E (Arg-117 and Arg-120), ␣-helix F (Lys-71, Arg-78,
Tyr-81, Lys-82) or ␤-strand 3A (Trp-177). It appears that multiple mutations or charge reversal mutations are needed to
observe a significant reduction in binding, as single alanine substitutions had less effect (Table 1). Remarkably, we also found a
significant reduction in the binding of a PAI-1 variant with
mutations in the flexible hinge region (R103A/M112A/
Q125A), which we reported previously as having a strongly
reduced binding via the SMB domain (18).
Because the R117E/R120E mutant form of PAI-1 was
severely impaired with regard to binding to the secondary site
in vitronectin, we determined the KD value for its binding to
r⌬sBVN by SPR using steady state measurements (Fig. 2). The
calculated dissociation constant from these data is ⬃480 nM,
compared with 25–50 nM for active, wild-type PAI-1.
Evaluation of the Binding of PAI-1 Mutants to Full-length
Vitronectin—As described above, mapping of the second site
for binding of PAI-1 to the deletion mutant of vitronectin
revealed that there were relatively small differences in affinities
for the active and latent forms of PAI-1. Furthermore, there was
no stabilization of the active conformation by r⌬sBVN,
although full-length vitronectin gave the well characterized
prolonged half-life. These observations indicated that it was
important to reevaluate the binding of PAI-1 to full-length
vitronectin in light of our new data indicating dual binding sites
on both proteins. For this reason, we pursued studies with wildtype PAI-1 and the mutants identified in the mapping experiments that defined the second binding site using SPR measurements with full-length vitronectin immobilized on the chip
surface.
The SPR analysis of binding of latent PAI-1 to full-length
vitronectin (Fig. 3) indicated that the binding kinetics fit well to
VOLUME 283 • NUMBER 42 • OCTOBER 17, 2008
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We also tested latent forms of
PAI-1 from the battery of mutants
used for the mapping studies for binding to full-length vitronectin (Fig. 3).
Among this large series of PAI-1
mutants,
K82E,
R117E/R120E,
R103A/M112A/Q125A, K71A/R78A/
Y81A/K82A, and W177F exhibited
an increased KD value as compared
with wild-type PAI-1 (Table 2).
Indeed, these are the same mutant
forms of PAI-1 that exhibit reduced
binding for r⌬sBVN. Thus, latent
PAI-1 binds to full-length vitronectin with kon, koff, and KD values similar to those found for the binding of
FIGURE 3. Analysis of the binding of latent PAI-1 to full-length vitronectin by SPR. The indicated PAI-1 variants active and latent PAI-1 to r⌬sBVN.
(latent form), in concentrations of 250 (black lines), 125 (gray lines), 63 (red lines), 32 (green lines), 16 (blue lines), 8 Moreover, the effects of the individ(orange lines), and 4 nM (magenta lines), were injected over a chip with ⬃3000 RU of full-length vitronectin at a flow
ual mutations in PAI-1 were similar
rate 30 l/min. After discontinuation of the injection, dissociation was followed for an additional 200 s.
in the two cases.
Nonetheless, a close inspection of the effects of some mutaTABLE 2
tions revealed small but significant differences in the binding of
Effect of mutations on the binding of latent PAI-1 to full-length
latent PAI-1 to r⌬sBVN and full-length VN. With r⌬sBVN on
vitronectin as analyzed by SPR
the chip, the R103A/M112A/Q125A mutant showed reduced
Latent PAI-1, in concentrations of 500, 250, 125, 63, 32, 16, 8, 4, and 0 nM, were
passed over a chip with approximately 3000 RU of full-length vitronectin at a flow
binding, but the K71A/R78A/Y81A/K82A form of PAI-1
rate of 30 ml/min. After 120 s, the injection was discontinued, and the dissociation
showed more severely impaired binding (Table 1). In contrast,
phase was followed. Means ⫾ S.D. and the number of experiments (in parentheses)
for the estimated KD values are indicated in the table. Other PAI-1 mutants with
in experiments using full-length vitronectin on the chip, the
single-point mutations that were tested but for which binding was not significantly
R103A/M112A/Q125A mutation reduced the binding 10-fold,
different (reduced by more than 50%) from the wild type were K71A, R78A, Y81A,
K82A, M85A, P87A, W88A, R117A, R120A, N174A, K178A, H231A, D233A, K90A,
whereas K71A/R78A/Y81A/K82A had a much weaker effect
S94A, T96A, E92A, and D91A.
(Table 2, Fig. 3).
PAI-1 variant
KD
Comparison of the Binding of Active and Latent Forms of
nM
PAI-1 Mutants to Full-length Vitronectin—The binding site for
a
Wild type
94 ⫾ 27 (8)
the SMB domain on PAI-1 has been well defined by x-ray crys177 ⫾ 98 (8)b
K82E
538 ⫾ 208 (3)b
tallography (15, 31) and site-directed mutagenesis (19, 21).
b
R117E/R120E
5282 ⫾ 4487 (7)
Because the mutants identified in this study (K82E, R117E/
R103A/M112A/Q125A
811 ⫾ 359 (5)b
K71A/R78A/Y81A/K82A
769 ⫾ 299 (5)b
R120E, R103A/M112A/Q125A, K71A/R78A, Y81A/K82A, and
b
W177F
⬎10,000 (5)
W177F) interact in the latent form at a site that is separate from
a
The data were fit to a 1:1 binding model using Biacore software. The KD value for
the recognition sequences for the SMB domain, it was imporwild-type PAI-1 was calculated as the ratio of the on- and off-rates: kon ⫽ 3.86 ⫾
2.56 ⫻ 105 M⫺1s⫺1 and koff ⫽ 3.39 ⫾ 2.11 ⫻ 10⫺2 s⫺1 (8 measurements each).
tant to complete our analysis and test for any effects of these
b
KD values were calculated manually from the PAI-1 concentration dependence of
mutagenized forms of PAI-1 in their active conformation on
the steady state binding values according to Equation 3 using the equilibrium
binding approach of Rich and Myzska (36) (see “Experimental Procedures”).
binding to full-length vitronectin, which contains the SMB
domain. In other words, the effects on affinity of these mutants
a simple 1:1 model. This is reasonable because the predominant in their latent form, where binding is mediated solely through
binding that occurs with the SMB domain is not observed with the second site, would be expected to be negligible for the active
latent forms of PAI-1, so that the sole binding interaction is that forms of these mutants, in which binding to full-length
mediated via the second site. Fitting the data to this 1:1 model vitronectin is dominated by the high affinity interaction at the
showed that latent PAI-1 bound to full-length vitronectin with SMB domain.
We tested for these effects using SPR, with full-length
an association rate constant of (3.86 ⫾ 2.56) ⫻ 105 M⫺1s⫺1, a
dissociation rate constant of (3.39 ⫾ 2.11) ⫻ 10⫺2 s⫺1, and an vitronectin immobilized on the chip and injection of the PAI-1
equilibrium dissociation constant of 94 ⫾ 27 nM (n ⫽ 9) (Table variants in their active form, in concentrations ranging from 0.4
2). Using an alternative approach, determining the KD value to 50 nM (Fig. 4). The binding kinetics were characterized by a
from the concentration dependence of the steady state binding fast association and a very slow dissociation. Because of the near
yielded a value of 177 ⫾ 98 nM. By both measures, the KD value immeasurable off-rates, we relied on our calculations for the
is thus ⬃2 orders of magnitude weaker than observed for the initial association rates to permit a meaningful comparison of
binding of active PAI-1 (18). Significantly, these rate constants, the relative binding of the mutants in a quantitative fashion.
as well as the equilibrium dissociation constant, were in good The rates were linearly related to the PAI-1 concentration
agreement with those for the binding of active and latent PAI-1 (Table 3). It is apparent from this analysis that the mutant forms
of PAI-1 with substitutions of K82E, R117E/R120E, and W177F
to r⌬sBVN (Fig. 2).
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isolated SMB caused a reduction in
binding of active PAI-1 to (0.45 ⫾
0.09 times the control value). In contrast, and as predicted, equimolar
amounts of isolated SMB strongly
competed the binding of active PAI-1
to full-length vitronectin (Fig. 5B). In
either case, with r⌬sBVN or fulllength vitronectin on the chip, the isolated SMB domain competed poorly
for the binding of latent PAI-1 to
either form of vitronectin; this result
is as expected because latent PAI-1
has a very low affinity for the SMB
domain.
In both cases, there is little or no
FIGURE 4. SPR analysis of the binding of active PAI-1 to full-length vitronectin. The indicated PAI-1 variants competition from the isolated SMB
(active form), in concentrations of 50 (black lines), 25 (gray lines), 12.5 (red lines), 6.25 (green lines), 3.13 (blue domain for binding to the second
lines), 1.56 (orange lines), and 0.78 nM (magenta lines), were injected over a chip with ⬃500 RU of full-length
vitronectin at a flow rate 30 l/min. After discontinuation of the injection, dissociation was followed for an site on PAI-1, either in binding to
r⌬sBVN or in binding of latent
additional 200 s.
forms of PAI-1 to full-length
TABLE 3
vitronectin. These results substantiate a second, weaker site for
Concentration dependence of initial association rate of active PAI-1
interaction between PAI-1 and vitronectin, which determines
binding to full-length vitronectin in SPR experiments
the interaction between both active and latent PAI-1 with
The indicated PAI-1 variants (active form), in concentrations of 50, 25, 12.5, 6.25,
r⌬sBVN, as well as the interaction of latent PAI-1 with full3.13, and 1.56 nM, were injected over a chip with approximately 500 RU of fulllength vitronectin. The observed binding curves are shown in Fig. 4. For each PAI-1
length vitronectin.
variant, the slopes of the initial linear portions of the association curves were calcuCharacterization of PAI-1 Mutants with Defective Binding
lated by linear regression analysis. The rates vary linearly with the PAI-1 concentration. The table shows means ⫾ S.D. for the indicated number of independent experto
the Second Site on Vitronectin—All of the mutant forms of
iments (in parentheses).
PAI-1
that were tested were fully active inhibitors of uPA as
PAI-1 variant
Rate
measured
by the formation of stable, covalent serpin-uPA com⫺1
⫺1
R s n M
plexes observed in SDS-PAGE. To further characterize the
Wild type
0.178 ⫾ 0.027 (6)
K82E
0.156 ⫾ 0.022 (3)
mutants that had a reduced binding to the second site, we measR117E/R120E
0.155 ⫾ 0.031 (5)
ured the half-life for their conversion to the latent state upon
R103A/M112A/Q125A
0.000 ⫾ 0.000 (5)
K71A/R78A/Y81A/K82A
0.059 ⫾ 0.023 (5)
incubation at 37 °C (Table 4). In agreement with previous findW177F
0.182 ⫾ 0.04 (5)
ings, wild-type PAI-1 had a half-life of a little more than 1 h. The
R103A/M112A/Q125A and K71A/R78A/Y81A/K82A forms of
differed little if at all from the wild-type protein in binding rates. PAI-1 did not differ from wild-type PAI-1 with respect to the
However, PAI-1 with K71A/R78A/Y81A/K82A had a some- half-life for transition to the latent form. The R117E/R120E
what reduced binding, and the R103A/M112A/Q125A mutant mutant had a somewhat prolonged half-life, and the K82E form
exhibited no measurable binding.
of PAI-1 exhibited a 3-fold shorter half-life. All variants but
Thus, the effects of specific mutations on the binding of R103A/M112A/Q125A PAI-1 exhibited the expected proactive PAI-1 to full-length vitronectin are unrelated to their longed half-life in the presence of vitronectin. This was as
effects on the binding of latent PAI-1 to full-length vitronectin.
expected because the R103A/M112A/Q125A form of PAI-1
Likewise, they are not directly correlated to the binding behavhas mutations in the flexible hinge region to disrupt binding to
ior observed with the r⌬sBVN deletion mutant.
the SMB domain. Because the W177F mutant was previously
Tests for Competition of the Isolated SMB Domain for Binding
reported to have a strongly prolonged half-life of more than 400
to Full-length Vitronectin and r⌬sBVN—The residues in PAI-1
min (44), the effects of vitronectin on the rate of conversation of
implicated for binding to the second site on vitronectin are
this variant to a latent form were not tested.
found outside of the previously identified SMB binding area.
Thus, the two vitronectin-binding sites on PAI-1 appear to be
separate and distinct, and thus binding of the isolated SMB DISCUSSION
Structural Determinants of the Second Binding Site on PAI-1
domain to PAI-1 should not prevent binding of PAI-1 to the
Are
Localized in the Distal Ends of Helices D and E and Are
second site on vitronectin. This possibility was explored using
Separate
from the SMB-binding Site—The results presented
SPR. Complexes of PAI-1 and the isolated SMB domain were
formed and then injected over immobilized r⌬sBVN. The iso- here are compatible with the hypothesis of a second, weaker
lated SMB domain, in slight molar excess, causes a partial com- interaction between PAI-1 and vitronectin, different from the
petition of the binding of 700 nM active PAI-1 to r⌬sBVN (see SMB domain-PAI-1 binding. This conclusion is based on three
representative data in Fig. 5A); in four independent experiments, types of evidence.
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SMB domain virtually eliminates
the high-affinity, slowly dissociating
binding to native vitronectin. Steric
effects may account for the small
degree of inhibition observed with
the SMB-PAI-1 complex binding to
r⌬sBVN because of the observed
proximity of the SMB domain-binding site and the second binding site.
The main PAI-1 binding determinants in the SMB domain are near a
single-turn ␣-helix housing residues 26 –30 and stabilized by an
FIGURE 5. Effect of isolated SMB domain on the binding of PAI-1 to r⌬sBVN or full-length vitronectin.
A, binding to r⌬sBVN. PAI-1 (0.7 M) was incubated for 30 min at room temperature in the absence or presence extensively disulfide-bonded doof a 2-fold molar excess of isolated SMB domain before injection at a flow rate of 20 l/min over a chip coated main structure (15, 26). Although
with 6000 RU of r⌬sBVN. B, binding to full-length vitronectin. PAI-1 (100 nM) was passed over a Biacore chip
coated with 3000 RU of monomeric vitronectin in the absence or presence of a 1.5-fold molar excess of isolated the core of the SMB domain, includSMB domain. The results in both panels for binding of PAI-1 are shown in the absence (solid lines) or presence ing residues 18 – 41, is well struc(dashed lines) of the SMB domain. In both panels, binding in the presence of the SMB domain is normalized tured, NMR measurements (26) and
relative to the of binding observed for PAI-1 alone.
x-ray crystallography (15) indicate
that the flanking regions extending
TABLE 4
Half-lives for conversion of PAI-1 variants to the latent form
beyond residue 42 are more disordered. It is therefore also posFor each PAI-1 variant, the specific inhibitory activity toward uPA was monitored
sible that the slight SMB domain inhibition is due to the overlap
over time at 37 °C; the rate of conversion to the latent form is expressed as the
of the SMB domain (residues 1–51 for the cyanogen bromide
functional half-life, t ⁄ . The averages ⫾ S.D. for the indicated number of independent experiments (in parentheses) are given. ND, not determined.
fragment (26) or residues 1– 47 for the recombinant SMB (29))
PAI-1 variant
Vitronectin
t⁄
and r⌬sBVN (residues 41– 458) and that this flexible region
min
(amino acids 42– 47) in the isolated SMB domain partially
Wild type
⫺
67 ⫾ 3 (15)
interferes with the binding of the PAI-1-SMB complex to fulla
⫹
121 ⫾ 17 (12)
R117E/R120E
⫺
109 ⫾ 8 (3)b
length vitronectin and r⌬sBVN.
⫹
158 ⫾ 22 (3)a
Third, a panel of PAI-1 mutants was used to define the
R103A/M112A/Q125A
⫺
59 ⫾ 3 (3)
⫹
45 ⫾ 4 (3)
surface that corresponds to a secondary vitronectin-binding
K71A/R78A/Y81A/K82A
⫺
59 ⫾ 4 (3)
site on PAI-1. Several mutants with multiple alanine substi⫹
127 ⫾ 4 (3)a
tutions or charge reversal mutations had a strong impact on
W177F
⫺
432 ⫾ 18 (3)b
⫹
ND
the binding. Mutants involving residues Lys-71, Arg-78, Tyrb
K82E
⫺
19 ⫾ 4 (3)
81, Lys-82, Arg-117, Arg-120, and Trp-177 were implicated
⫹
138 ⫾ 4 (3)a
a
Significantly larger than the corresponding value in the absence of vitronectin
in the secondary site. These residues are clustered on the
(p ⱕ 0.01).
surface of ␣-helix D and ␣-helix E and at the C-terminal end
b
Significantly different from the corresponding value for wild-type PAI-1 (p ⱕ 0.01).
of ␤-strand 3A (Fig. 6). Both ribbon and space-filling models,
First, analyses of the binding kinetics led us to conclude that which highlight the location of the second binding site on
latent PAI-1 binds to full-length vitronectin and r⌬sBVN with PAI-1 concomitantly with the primary site in the flexible
similar kon, koff, and KD values. Active PAI-1 binds to r⌬sBVN joint region, are shown in the figure. Likewise, monoclonal
with kinetics similar to that for the binding of latent PAI-1 to antibodies with epitopes in the ␣-helix D–␤-strand 2A area
full-length vitronectin and r⌬sBVN, but it binds much tighter were found to inhibit binding. Among the mutations tested,
to full-length vitronectin. Whereas SMB domain binding dom- the most pronounced effects on binding were observed with
inates the interaction of full-length vitronectin with active PAI-1 mutants harboring cumulative mutations, whereas
PAI-1, the absence of this interaction in the mutant form of single amino acid substitutions had less striking effects. This
vitronectin engineered without the SMB domain and in the fact, in conjunction with the relative large area over which
binding of latent PAI-1 to full-length vitronectin makes it pos- the mutants are spread, suggests an extended interaction
surface resulting from relatively weak contributions to the
sible to map the contributions from the second, weaker site.
Second, from the hypothesis of two separate and distinct binding energy from individual residues.
Despite the fact that multiple mutations are most effective
vitronectin-binding sites on PAI-1, one would predict that
interactions of PAI-1 with the SMB domain should not prevent in disrupting binding to the second site, the effects of the
PAI-1 binding to the second site in vitronectin. In experiments mutations themselves do not appear to be the result of extendesigned to test this idea, complexes of active PAI-1 bound to sive structural changes or disordering. The mutant forms of
the isolated SMB domain were shown to bind to r⌬sBVN, albeit PAI-1 typically exhibited normal function. For instance, the
the binding was somewhat diminished compared with that for R103A/M112A/Q125A mutant has only a slightly increased
free PAI-1. In contrast, evaluation of the binding of active PAI-1 rate at which it is converted to the latent form, and it exhibits
to full-length vitronectin by SPR, in the absence and presence of normal binding to endocytosis receptors (18). Although two
the SMB domain, showed that saturation of PAI-1 with the mutants (R117E/R120E and K82E) differed somewhat from
12

12
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FIGURE 6. PAI-1 structures indicating the regions important in interacting with primary and secondary sites on vitronectin. A, a ribbon structure
for active PAI-1 (Protein Data Bank accession code 1OC0), with the central ␤-sheet A shown in blue and the C-sheet in orange. The RCL, which is not
observed in the crystal structure because of its mobility, is represented by the hashed line connecting the N- and C-terminal ends. B and C, space-filling
models of active PAI-1 (Protein Data Bank accession code 1OC0) and latent PAI-1 (Protein Data Bank accession code 1LJ5), respectively. Amino acids
identified as involved in binding to r⌬sBVN in SPR experiments are color-coded, with residues associated with mutations that exhibit impaired binding
to r⌬sBVN shown in red (see Table 1). For reference, PAI-1 residues that are involved in binding to the SMB domain of vitronectin are colored green (15,
38), The mutations R103A/M112A/Q125A, which reduce binding to both the SMB domain and r⌬sBVN, are shown in yellow, and the residues for which
point mutations have no effect on binding to the to r⌬sBVN chip are shown in cyan. The magenta ribbon structures in A and B represent the SMB domain
complexed with PAI-1 (15).

wild-type PAI-1 with respect to the rates of transition to the
latent form, they give the normal response upon addition of
vitronectin, with prolonged half-lives for conversion to the
latent conformation. Thus, most mutations resulting in a
reduced binding to the second site did not affect the binding
to full-length vitronectin via the SMB domain. Of course, an
exception is PAI-1 with the R103A/M112A/Q125A mutations, which was engineered as a PAI-1 variant without
measurable affinity to full-length vitronectin via the SMB
domain (18). This mutant does not bind the SMB domain
and thus did not respond to vitronectin in this fashion. Conversely, the W177F mutant identified in this study was previously shown to be “stable,” such that it converts to the
latent form at an extremely slow rate (44) and does not
require SMB binding to stabilize the active conformation. In
summary, the remarkable clustering of the mutations identified to interact with the second binding site present on
r⌬sBVN indicates that these residues together define a more
extended interaction surface for vitronectin than previously
recognized.
The Second Binding Site Outside of the SMB Domain Only
Weakly Discriminates between Active and Latent Forms of
PAI-1—Latent PAI-1 is known to exhibit greatly diminished
binding to vitronectin (45). This phenomenon is well understood, as there are significant structural differences between
active and latent PAI-1 at the base of the A-sheet at the ends
of helices D, E, and F that deform the primary binding surface in the region that interacts with the SMB domain (13,
15, 19, 21). In contrast, latent PAI-1 binds to the secondary
site in vitronectin with similar kinetics and affinity com-
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pared with the binding observed with active PAI-1. Comparison of the structures of active and latent PAI-1 shows some
changes in the positions of helices D and E, but the relatively
contiguous nature of the secondary binding site surface on
PAI-1 is maintained (Fig. 6).
Previous work, based on enzyme-linked immunosorbent
assays to compare the various conformations of PAI-1 in
terms of binding to vitronectin, suggests a large difference in
binding affinity when comparing active and latent forms of
PAI-1 (45). The current study supports these findings; however, detectable binding of latent PAI-1 to full-length and
truncated vitronectin lacking the SMB domain was detected
by SPR. Latent PAI-1 bound to vitronectin at this second site,
and the SPR studies showed that the affinity was weaker than
observed for the interaction within the SMB domain. The
studies comparing binding of latent and active forms of
PAI-1 to the second site revealed that the weak binding was
due to appreciable off-rates (dissociation rate constants)
that were nearly equivalent for latent and active forms of the
serpin. Furthermore, binding the mutant form of vitronectin, which lacks the primary site for PAI-1 binding in the
SMB domain, did not stabilize PAI-1 activity, so that it lost
activity as it converted to the latent form at nearly the same
rate as in the absence of vitronectin. Thus, this secondary
binding site does not appear to play a role in one of the main
known functions of vitronectin, that of stabilizing the active
form of PAI-1.
What Is the Role of Two Complementary Binding Sites on
Vitronectin and PAI-1?—The interaction between vitronectin via the SMB domain with PAI-1 has been well characterVOLUME 283 • NUMBER 42 • OCTOBER 17, 2008
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ized. However, our mutagenesis approach and prior biophysical studies have pointed to a more complex binding
scenario that involves regions outside of this primary binding site, between the flexible joint region and SMB domain.
Early clues that suggested this model came from analytical
ultracentrifugation on the PAI-1-vitronectin complex. That
study demonstrated that two molecules of PAI-1 could bind
to a single molecule of vitronectin, with assembly to a 4:2
(PAI-1:vitronectin) intermediate well populated at micromolar concentrations of the proteins (9). Further work using
sedimentation velocity measurements in the ultracentrifuge
clarified the concentration dependence of assembly of higher-order PAI-1-vitronectin complexes and suggested a stepwise mechanism for their assembly by which the primary,
high-affinity site in the SMB domain is bound first followed
by occupation of a second, lower affinity site at higher concentrations of PAI-1 (10). In the present study using SPR, any
effects of PAI-1 that induce higher order complexes cannot
occur and will not affect the results because vitronectin is
covalently cross-linked to the chip.
The functional effects of these more extensive PAI-1vitronectin interactions remain to be established. The KD for
the binding of PAI-1 to the second site in isolation is high
relative to circulating levels of PAI-1. With PAI-1 concentrations in vivo in the low nanomolar range, a KD value in the
high nanomolar range would lead to very little binding.
However, the concentration of PAI-1 in the extracellular
environment in tissue has been reported to be much higher,
approaching levels at which this binding event becomes significant, especially under pathological scenarios (46 –50).
Also, even at nanomolar concentrations, the presence of two
binding sites will favor formation of a more extended binding surface comprised of both sites when the two proteins
are juxtaposed by interaction at the primary, high-affinity
site involving the SMB domain. A likely model for the PAI1-vitronectin binding is that a single PAI-1 molecule binds
one vitronectin molecule via an interaction involving both
the first and the second site. The pathway for binding could
consist of an initial docking of the SMB domain onto the
flexible hinge region of PAI-1 followed by the establishment
of an extended interaction that involves the secondary sites.
An exciting possibility is that that the second site is necessary for inducing higher order structures of vitronectin oligomers, which might be deposited in the extracellular matrix
and promote cell adhesion.
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